13.05.2024, 15:30
Ntmb Biologists Give Bacteria Thermostat Controls
KARACHI:Late-day selling wiped off all gains equities made during intra-day trading as the benchmark-100 index closed marginally lower after a volatile session.The earlier half of the day saw the KSE-100 reach a new record high, moving past the 42,400-point mark, but profit-taking by a few foreign investors ahead of the US elections pushed the index in the red.At close, the Pakistan Stock Exchange鈥檚 benchmark KSE 100-share Index recorded a fall of 0.05% or 19.63 points to finish at 42,113.91.Elixir Securities, in its report, stated that the wider market carried positive momentum from Monday and opened gap up on good volumes as investors took cues from higher global equity markets and relative political calmness on domestic front.鈥淐ements gained traction over release of higher monthly local sales number and approval of key local infrastructure projects and nb balance led earl adidas samba y gains, while notable blue chip names and sideboard plays also supported the upward ride,鈥?said analyst Ali Raza stanley-cup .鈥淗owever, Seattle Genetics, Inc. has announced that it will report preclinical advances with its antibody-drug conjugate (ADC) technology during the 2005 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held November 14-18, 2005 at the聽Pennsylvania Convention Center in Philadelphia. In addition, two of Seattle Genetics' co new balance 480 llaborators,聽CuraGen and MedImmune, will make presentations regarding their ADC programs utilizing Seattle Genetics' technology. "We are continuing to make significant strides with our ADC technology, which we employ in our own product pipeline, including SGN-35 and SGN-75, as well as license to l yeezy slide eading biotechnology and pharmaceutical companies," stated Clay B. Si damen jordans egall, Ph.D., President and Chief Executive Officer at Seattle Genetics. "The presentations at this conference by Seattle Genetics and our collaborators demonstrate some of the key advances being made with our technology to empower the next generation of targeted cancer therap
KARACHI:Late-day selling wiped off all gains equities made during intra-day trading as the benchmark-100 index closed marginally lower after a volatile session.The earlier half of the day saw the KSE-100 reach a new record high, moving past the 42,400-point mark, but profit-taking by a few foreign investors ahead of the US elections pushed the index in the red.At close, the Pakistan Stock Exchange鈥檚 benchmark KSE 100-share Index recorded a fall of 0.05% or 19.63 points to finish at 42,113.91.Elixir Securities, in its report, stated that the wider market carried positive momentum from Monday and opened gap up on good volumes as investors took cues from higher global equity markets and relative political calmness on domestic front.鈥淐ements gained traction over release of higher monthly local sales number and approval of key local infrastructure projects and nb balance led earl adidas samba y gains, while notable blue chip names and sideboard plays also supported the upward ride,鈥?said analyst Ali Raza stanley-cup .鈥淗owever, Seattle Genetics, Inc. has announced that it will report preclinical advances with its antibody-drug conjugate (ADC) technology during the 2005 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held November 14-18, 2005 at the聽Pennsylvania Convention Center in Philadelphia. In addition, two of Seattle Genetics' co new balance 480 llaborators,聽CuraGen and MedImmune, will make presentations regarding their ADC programs utilizing Seattle Genetics' technology. "We are continuing to make significant strides with our ADC technology, which we employ in our own product pipeline, including SGN-35 and SGN-75, as well as license to l yeezy slide eading biotechnology and pharmaceutical companies," stated Clay B. Si damen jordans egall, Ph.D., President and Chief Executive Officer at Seattle Genetics. "The presentations at this conference by Seattle Genetics and our collaborators demonstrate some of the key advances being made with our technology to empower the next generation of targeted cancer therap